摘要
目的分析江苏地区肿瘤患者临床分离菌分布特点及耐药率。方法收集2021年“江苏省细菌耐药监测网”肿瘤患者临床分离菌耐药监测数据,结果判断参照CLSI 2021年版标准,用WHONET 5.6软件统计分析。结果收集肿瘤患者分离菌17541株,以革兰阴性菌(76.9%)为主,前5位菌属是大肠埃希菌(22.2%)、克雷伯菌属(19.8%)、铜绿假单胞菌(9.2%)、金黄色葡萄球菌(7.9%)和不动杆菌属(7.5%),标本来源前3位是呼吸道(38.4%)、尿液(24.2%)和血液(21.7%);大肠埃希菌和肺炎克雷伯菌对亚胺培南和美罗培南的耐药率分别为2.6%和8.6%、3.4%和10.2%;鲍曼不动杆菌对所有监测药物的耐药率均<22%;金黄色葡萄球菌和凝固酶阴性葡萄球菌对甲氧西林耐药株检出率分别为36.2%和66.8%。结论江苏地区肿瘤患者分离菌以革兰阴性菌为主,血流感染率较高,主要分离菌对抗菌药物的耐药率比一般人群低。
Objective To investigate the distribution and analyze the drug resistance of bacteria isolated from cancer patients in Jiangsu Province.Methods The drug resistance surveillance data of the pathogenic bacteria isolated from tumor patients in Jiangsu Antimicrobial Resistance Surveillance System in 2021 were collected,and the results were judged referring to CLSI 2021breakpoints.WHONET 5.6 software was used for statistical analysis.Results A total of 17541 isolates were collected from tumor patients,with gram-negative bacilli(76.9%)as the main strain.The top 5 common isolates were E.coli(22.2%),Klebsiella spp.(19.8%),P.aeruginosa(9.2%),S.aureus(7.9%)and Acinetobacter spp.(7.5%).The top 3 sources of bacteria were respiratory(38.4%),urine(24.2%)and blood(21.7%).The resistance rates of E.coli and K.pneumonia to imipenem and meropenem were 2.6%,8.6%and 3.4%,10.2%.The drug resistance of A.baumanii to other surveilled drugs was less than 22%.The detection rate of S.aureus and coagulase negative Staphylococcus to methicillin was 36.2%and66.8%.Conclusion Gram-negative bacilli was the main pathogenic bacteria of cancer patients in Jiangsu area,of which blood infection rate was relatively high.And the drug resistant rate of isolated strains in cancer patients was less than that in normal people.
作者
俞心念
唐莉
程梅
YU Xin-nian;TANG Li;CHENG Mei(Department of Medical Oncology,Jiangsu Cancer Hospital,Jiangsu Institute of Cancer Research,Affiliated Cancer Hospital of Nanjing Medical University,Nanjing,Jiangsu 210009,China;不详)
出处
《中国卫生检验杂志》
CAS
2022年第21期2565-2569,共5页
Chinese Journal of Health Laboratory Technology
基金
国家科技基础资源调查专项(2019FY101200,2019FY-101205)。
关键词
肿瘤
抗菌药物
耐药监测
Tumor
Antibacterial agents
Resistance surveillance